このエントリーをはてなブックマークに追加
ID 66030
FullText URL
Author
Uka, Mayu Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
Iguchi, Toshihiro Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine Kaken ID
Okawa, Nanako Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
Matsui, Yusuke Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
Tomita, Koji Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
Umakoshi, Noriyuki Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
Munetomo, Kazuaki Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
Gobara, Hideo Division of Medical Informatics, Okayama University Hospital ORCID Kaken ID publons researchmap
Araki, Motoo Department of Urology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine ORCID Kaken ID publons researchmap
Hiraki, Takao Department of Radiology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine Kaken ID publons researchmap
Abstract
Purpose To retrospectively assess the feasibility, safety, renal function, technique efficacy rate, and survival of patients with clinical T3a renal cell carcinoma (RCC).
Materials and methods Sixteen cryoablation sessions were performed in 14 patients (10 men; mean age, 69.8 ± 10.5 years; range, 49–90 years) with 14 clear cell T3a RCCs (mean, 3.3 ± 0.9 cm; range, 1.9–5.2 cm). One patient was on dialysis. Transcatheter arterial embolization was performed before cryoablation in 15 sessions. The primary endpoint was the technique efficacy rate. The secondary endpoints included feasibility, safety, renal function, and survival.
Results Cryoablation was technically successful in all RCC cases. In two RCCs, cryoablation was performed twice because of local tumor progression. No major adverse events were observed. All patients were alive without metastases, with a median follow-up of 45 months (6−93 months). Complete response was achieved by cryoablation in 11 RCCs (78.6%). The primary and secondary technique efficacy rates were 77.1% and 84.4% at 1 year, 57.9% and 73.9% at 3 years, and 57.9% and 73.9% at 5 years, respectively. One patient underwent dialysis given a total contralateral nephrectomy due to another RCC 1 month after initial cryoablation and a total ipsilateral nephrectomy 46 months after initial cryoablation due to local progression. Except for two dialysis patients, of the 12 patients with a median follow-up of 41 months (6–93 months), none were on dialysis.
Conclusion Cryoablation was safe and effective in T3a RCC, which mainly involved the renal venous branches and may represent an alternative treatment for inoperable patients.
Keywords
Kidney neoplasms
Cryosurgery
Image-guided
Note
The version of record of this article, first published in Japanese Journal of Radiology, is available online at Publisher’s website: http://dx.doi.org/10.1007/s11604-022-01297-8
Published Date
2022-06-21
Publication Title
Japanese Journal of Radiology
Volume
volume40
Issue
issue11
Publisher
Springer Science and Business Media LLC
Start Page
1201
End Page
1209
ISSN
1867-1071
NCID
AA12375935
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© The Author(s) 2022
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1007/s11604-022-01297-8
License
http://creativecommons.org/licenses/by/4.0/
Citation
Uka, M., Iguchi, T., Okawa, N. et al. Percutaneous cryoablation for clinical T3a renal cell carcinoma (< 7 cm) with segmental vein involvement or perinephric fat invasion based on preoperative evaluation of high-resolution multidetector computed tomography scan. Jpn J Radiol 40, 1201–1209 (2022). https://doi.org/10.1007/s11604-022-01297-8